Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
Phase III multicenter randomized, open-label study comparing the efficacy of a combined high dose chemotherapy using melphalan and bortezomib versus melphalan alone followed by stem cell transplant in frontline multiple myeloma patients, non-progressive after induction therapy.
Multiple Myeloma
DRUG: Bortezomib-Melphalan|DRUG: Melphalan
Complete Response rates (according to IMWG 2011 criteria), 60 days post Autologous Stem Cells Transplantation|overall survival, 60 months
Response rates (according to IMWG 2011 criteria), Compare response rate after ASCT and after the completion of consolidation therapy, post ASCT and consolidation therapy|Serious adverse event, End of study|progression-free survival between the two arms, 60 months
Phase III multicenter randomized, open-label study comparing the efficacy of a combined high dose chemotherapy using melphalan and bortezomib versus melphalan alone followed by stem cell transplant in frontline multiple myeloma patients, non-progressive after induction therapy.